JP2005527560A - Ｃｄｋ阻害剤とドキソルビシンとを含む組合せ - Google Patents

Ｃｄｋ阻害剤とドキソルビシンとを含む組合せ Download PDF

Info

Publication number
JP2005527560A
JP2005527560A JP2003579873A JP2003579873A JP2005527560A JP 2005527560 A JP2005527560 A JP 2005527560A JP 2003579873 A JP2003579873 A JP 2003579873A JP 2003579873 A JP2003579873 A JP 2003579873A JP 2005527560 A JP2005527560 A JP 2005527560A
Authority
JP
Japan
Prior art keywords
doxorubicin
cdk inhibitor
roscovitine
cdk
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003579873A
Other languages
English (en)
Japanese (ja)
Inventor
ロジャー ニール スレイ
アントン バーンズ
ヘレン マリー コリィー
スコット リオンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207228A external-priority patent/GB0207228D0/en
Priority claimed from GB0222408A external-priority patent/GB0222408D0/en
Priority claimed from GB0225876A external-priority patent/GB0225876D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of JP2005527560A publication Critical patent/JP2005527560A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003579873A 2002-03-27 2003-03-25 Ｃｄｋ阻害剤とドキソルビシンとを含む組合せ Withdrawn JP2005527560A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0207228A GB0207228D0 (en) 2002-03-27 2002-03-27 Use
GB0222408A GB0222408D0 (en) 2002-09-26 2002-09-26 Use
GB0225876A GB0225876D0 (en) 2002-11-06 2002-11-06 Use
PCT/GB2003/001282 WO2003082337A1 (fr) 2002-03-27 2003-03-25 Combinaison comprenant un inhibiteur de cdk et de la doxorubicine

Publications (1)

Publication Number Publication Date
JP2005527560A true JP2005527560A (ja) 2005-09-15

Family

ID=28678579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579873A Withdrawn JP2005527560A (ja) 2002-03-27 2003-03-25 Ｃｄｋ阻害剤とドキソルビシンとを含む組合せ

Country Status (7)

Country Link
EP (1) EP1487495A1 (fr)
JP (1) JP2005527560A (fr)
CN (1) CN1655821A (fr)
AU (1) AU2003217024A1 (fr)
BR (1) BR0308756A (fr)
MX (1) MXPA04009396A (fr)
WO (1) WO2003082337A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287718A1 (en) * 2003-11-06 2007-12-13 Green Simon R Methods for the Treatment of Multiple Myeloma Using Roscovitine
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
WO2007132220A1 (fr) * 2006-05-12 2007-11-22 Cyclacel Limited Combinaison de 4-hétér0aryl-pyrimidine amine substituée en 2 et d'un médicament cytotoxique, son utilisation dans le traitement d'un trouble prolifératif
CN103169720B (zh) * 2011-12-21 2016-12-07 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044174A2 (fr) * 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company Derives de 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one et leur utilisation
AU2002228849A1 (en) * 2000-12-08 2002-06-18 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
AU2003217024A1 (en) 2003-10-13
CN1655821A (zh) 2005-08-17
EP1487495A1 (fr) 2004-12-22
MXPA04009396A (es) 2005-01-25
BR0308756A (pt) 2004-12-28
WO2003082337A1 (fr) 2003-10-09

Similar Documents

Publication Publication Date Title
US10010536B2 (en) Method of modulating stress-activated protein kinase system
KR101667641B1 (ko) 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합
US8399420B2 (en) Azacytidine analogues and uses thereof
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
AU2017204436B2 (en) Treatment of diseases involving mucin
US20190314396A1 (en) Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
JP5457196B2 (ja) Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
US20180305330A1 (en) Materials and method for inhibiting replication protein a and uses thereof
KR20070085677A (ko) 만성 림프성 백혈병의 치료 방법 및 치료 조성물
JP2005527560A (ja) Ｃｄｋ阻害剤とドキソルビシンとを含む組合せ
US10744133B2 (en) Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling
US20090306098A1 (en) Combination of roscovitine and a hdca inhibitor to treat proliferative diseases
US20050222054A1 (en) Combination comprising a CDK inhibitor and doxorubicin
KR101466377B1 (ko) 디메톡시페닐디히드로피라졸릴나프탈레놀 유도체 및 그 제법 및 항암제로서의 용도
US7199161B2 (en) Substituted bicylo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
US7135501B2 (en) Clusianon isomers and use thereof
Bonomo et al. Evaluation of Synergistic Effect of Heteroaryl-Ethylene Molecules in Combination with Antibiotics: A Preliminary Study on Control Strains
RU2487883C2 (ru) Аналоги азацитидина и их применение
AU2012216834A1 (en) Pyridone Derivatives for Modulating Stress-Activated Protein Kinase System

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060323

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081205